These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 22965162)

  • 1. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
    Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
    Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.
    Piao Y; Liang J; Holmes L; Henry V; Sulman E; de Groot JF
    Clin Cancer Res; 2013 Aug; 19(16):4392-403. PubMed ID: 23804423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
    Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
    Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
    Mésange P; Poindessous V; Sabbah M; Escargueil AE; de Gramont A; Larsen AK
    Oncotarget; 2014 Jul; 5(13):4709-21. PubMed ID: 25015210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
    Navis AC; Hamans BC; Claes A; Heerschap A; Jeuken JW; Wesseling P; Leenders WP
    J Pathol; 2011 Apr; 223(5):626-34. PubMed ID: 21341272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
    Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
    Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
    Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
    Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
    Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
    Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
    Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.
    Mittal K; Koon H; Elson P; Triozzi P; Dowlati A; Chen H; Borden EC; Rini BI
    Cancer Biol Ther; 2014 Aug; 15(8):975-81. PubMed ID: 24842548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct effect of bevacizumab on glioblastoma cell lines in vitro.
    Simon T; Coquerel B; Petit A; Kassim Y; Demange E; Le Cerf D; Perrot V; Vannier JP
    Neuromolecular Med; 2014 Dec; 16(4):752-71. PubMed ID: 25113866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
    Lacal PM; Graziani G
    Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma.
    Keunen O; Johansson M; Oudin A; Sanzey M; Rahim SA; Fack F; Thorsen F; Taxt T; Bartos M; Jirik R; Miletic H; Wang J; Stieber D; Stuhr L; Moen I; Rygh CB; Bjerkvig R; Niclou SP
    Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3749-54. PubMed ID: 21321221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.